Clinical Trial Update: Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB. [Phase 1]

View source ↗

Summary

Phase 1 trial update reporting on safety and immunogenicity of the MVA85A TB vaccine in volunteers latently infected with tuberculosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• MVA85A (Modified Vaccinia Ankara expressing antigen 85A)

Snippet

Sponsor: University of Oxford | Conditions: Tuberculosis | Phase 1 | Status: COMPLETED